TY - JOUR
T1 - HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program
AU - Tabrizi, S.N.
AU - Brotherton, J.M.L.
AU - Stevens, M.P.
AU - Condon, J.R.
AU - Mcintyre, P.B.
AU - Smith, David
AU - Garland, S.M.
PY - 2014
Y1 - 2014
N2 - Background: Data on the prevalence of cervical HPV genotypes in Australia by age and by grade of cytological abnormality are sparse. Objective: Measure prevalence of HPV genotypes among 2620 Australian women by age and cytology status. Study design: Women presenting for routine Pap smear screening were recruited from diverse regions, including a significant sample of Indigenous women. DNA extracts prepared from Thinprep specimens were HPV genotyped by Roche LINEAR ARRAY HPV. Results: HPV prevalence and genotype distribution were stratified by age (mean 32.6. y) and Pap smear result (cytology normal in 86.7%). Overall HPV prevalence was 38.7% with high-risk HPV prevalence of 26.5%. Prevalence of HPV (66.3% in women. . 40. y), multiple HPV infection (45.5% in 40. y) and vaccine-targeted genotypes (HPV 6/11/16/18) (34.1% in 40. y) declined significantly with age. The six most common genotypes were: HPV 16 (8.3%), 51 (5.1%), 53 (4.7%), 62 (4.3%), 89 (3.9%) and 52 (3.8%). HR-HPV prevalence increased from 21.1% in women with normal cytology to 80.9% in those with cytologically predicted high-grade abnormalities (HGAs) (p
AB - Background: Data on the prevalence of cervical HPV genotypes in Australia by age and by grade of cytological abnormality are sparse. Objective: Measure prevalence of HPV genotypes among 2620 Australian women by age and cytology status. Study design: Women presenting for routine Pap smear screening were recruited from diverse regions, including a significant sample of Indigenous women. DNA extracts prepared from Thinprep specimens were HPV genotyped by Roche LINEAR ARRAY HPV. Results: HPV prevalence and genotype distribution were stratified by age (mean 32.6. y) and Pap smear result (cytology normal in 86.7%). Overall HPV prevalence was 38.7% with high-risk HPV prevalence of 26.5%. Prevalence of HPV (66.3% in women. . 40. y), multiple HPV infection (45.5% in 40. y) and vaccine-targeted genotypes (HPV 6/11/16/18) (34.1% in 40. y) declined significantly with age. The six most common genotypes were: HPV 16 (8.3%), 51 (5.1%), 53 (4.7%), 62 (4.3%), 89 (3.9%) and 52 (3.8%). HR-HPV prevalence increased from 21.1% in women with normal cytology to 80.9% in those with cytologically predicted high-grade abnormalities (HGAs) (p
U2 - 10.1016/j.jcv.2014.04.013
DO - 10.1016/j.jcv.2014.04.013
M3 - Article
C2 - 24854516
VL - 60
SP - 250
EP - 256
JO - Journal of Clinical Virology
JF - Journal of Clinical Virology
SN - 1386-6532
IS - 3
ER -